Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants
(Thomson Reuters ONE) -
KVISTGAARD, Denmark, May 18, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY)
announced today that the Company's share capital has been increased by nominally
DKK 800,000 as a consequence of employees' exercise of warrants.
The capital increase is effected without any pre-emption rights for the existing
shareholders of the Company or others. A total of 80,000 new shares are
subscribed for in cash at DKK 54.10 per share of nominally DKK 10. The total
proceeds to Bavarian Nordic A/S from the capital increase amounts to DKK 4.3
million.
Each share of nominally DKK 10 carries one vote at general meetings in the
Company. The new shares give rights to dividend and other rights in the Company
from the time of subscription. The new shares are expected to be admitted to
trading and official listing on Nasdaq Copenhagen on May 19, 2015. After
registration of the capital increase with the Danish Business Authority,
Bavarian Nordic A/S' share capital amounts to DKK 278,119,930.
The revised Articles of Association will be published separately and will
subsequently be available on the Company's website.
The content of this announcement does not affect the Company's expectations for
the financial results for 2015.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
About Bavarian Nordic
Bavarian Nordic is a biopharmaceutical company focused on the development and
manufacturing of cancer immunotherapies and vaccines for infectious diseases.
Through a long-standing collaboration with the U.S. Government, Bavarian Nordic
has developed a portfolio of biological countermeasures, including the non-
replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use
by the U.S. and other governments. The vaccine is approved in the EU (under the
trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are
pioneering the development of an Ebola vaccine, which has been fast-tracked by
authorities in response to the current situation in West Africa. Additionally,
in collaboration with the National Cancer Institute, Bavarian Nordic has
developed a portfolio of active cancer immunotherapies based on its versatile
pox-virus based technologies, including PROSTVAC®, which is currently in Phase
3 clinical development for the treatment of advanced prostate cancer. The
company has partnered with Bristol-Myers Squibb for the potential
commercialization of PROSTVAC. For more information visit www.bavarian-
nordic.com or follow us on Twitter (at)bavariannordic.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
201515uk:
http://hugin.info/100065/R/1922068/688962.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
[HUG#1922068]
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2015 - 11:45 Uhr
Sprache: Deutsch
News-ID 393872
Anzahl Zeichen: 4240
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 140 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
